{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:04:22Z","timestamp":1791867862065,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002494"],"award-info":[{"award-number":["UL1TR002494"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA77598"],"award-info":[{"award-number":["P30 CA77598"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.eprac.2021.11.085","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T21:27:11Z","timestamp":1637962031000},"page":"271-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Screening Rate for Primary Aldosteronism Among Patients With Apparent Treatment-Resistant Hypertension: Retrospective Analysis of Current Practice"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6787-5846","authenticated-orcid":false,"given":"Kidmealem","family":"Zekarias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn M.","family":"Tessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.eprac.2021.11.085_bib1","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.eprac.2021.11.085_bib2","year":"2019"},{"issue":"5","key":"10.1016\/j.eprac.2021.11.085_bib3","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.eprac.2021.11.085_bib4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"S3","key":"10.1016\/j.eprac.2021.11.085_bib5","doi-asserted-by":"crossref","first-page":"20A","DOI":"10.1016\/S0895-7061(02)02325-7","article-title":"OR-46: high prevalence of primary aldosteronism among black and white subjects with resistant hypertension","volume":"15","author":"Calhoun","year":"2002","journal-title":"Am J Hypertens"},{"issue":"5","key":"10.1016\/j.eprac.2021.11.085_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.jhh.1001554","article-title":"Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region","volume":"17","author":"Strauch","year":"2003","journal-title":"J\u00a0Hum Hypertens"},{"issue":"11","key":"10.1016\/j.eprac.2021.11.085_bib7","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","article-title":"Low-renin status in therapy-resistant hypertension: a clue to efficient treatment","volume":"22","author":"Eide","year":"2004","journal-title":"J\u00a0Hypertens"},{"issue":"8","key":"10.1016\/j.eprac.2021.11.085_bib8","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2021.11.085_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Intern Med"},{"issue":"14","key":"10.1016\/j.eprac.2021.11.085_bib10","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.eprac.2021.11.085_bib11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.eprac.2021.11.085_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2021.11.085_bib13","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.119.14359","article-title":"Screening rates for primary aldosteronism in resistant hypertension: a cohort study","volume":"75","author":"Jaffe","year":"2020","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.eprac.2021.11.085_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.surg.2019.05.087","article-title":"Adherence to consensus guidelines for screening of primary aldosteronism in an urban healthcare system","volume":"167","author":"Sivarajah","year":"2020","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.eprac.2021.11.085_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.surg.2018.05.085","article-title":"Keeping primary aldosteronism in mind: deficiencies in screening at-risk hypertensives","volume":"165","author":"Ruhle","year":"2019","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.eprac.2021.11.085_bib16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1530\/EJE-11-0914","article-title":"Confirmatory testing in primary aldosteronism: extensive medication switching is not needed in all patients","volume":"166","author":"Solar","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2021.11.085_bib17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2265.2002.01613.x","article-title":"Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism","volume":"57","author":"Seifarth","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.eprac.2021.11.085_bib18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0272-6386(01)80117-7","article-title":"Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio","volume":"37","author":"Gallay","year":"2001","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.eprac.2021.11.085_bib19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: practical clinical perspectives","volume":"285","author":"Young Jr WF","year":"2019","journal-title":"J\u00a0Intern Med"},{"issue":"27","key":"10.1016\/j.eprac.2021.11.085_bib20","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1097\/MD.0000000000000162","article-title":"Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT)","volume":"93","author":"V\u00e1clav\u00edk","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.eprac.2021.11.085_bib21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00268-017-4311-1","article-title":"Refining the definitions of biochemical and\u00a0clinical cure for primary aldosteronism using the primary aldosteronism surgical outcome (PASO) classification system","volume":"42","author":"Miller","year":"2018","journal-title":"World J Surg"},{"issue":"4","key":"10.1016\/j.eprac.2021.11.085_bib22","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1161\/HYPERTENSIONAHA.119.13463","article-title":"Clinical outcomes of 1625 patients with primary aldosteronism subtyped with adrenal vein sampling","volume":"74","author":"Rossi","year":"2019","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.eprac.2021.11.085_bib23","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"de la Sierra","year":"2011","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.eprac.2021.11.085_bib24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.113.01448","article-title":"Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network","volume":"62","author":"Egan","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.eprac.2021.11.085_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2016.05.044","article-title":"Lack of control of hypertension in primary cardiovascular disease prevention in Europe: results from the EURIKA study","volume":"218","author":"Borghi","year":"2016","journal-title":"Int J Cardiol"},{"issue":"13","key":"10.1016\/j.eprac.2021.11.085_bib26","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant\u00a0hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.eprac.2021.11.085_bib27","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1097\/HJH.0b013e32834a8a42","article-title":"Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk","volume":"29","author":"Gupta","year":"2011","journal-title":"J\u00a0Hypertens"},{"issue":"5","key":"10.1016\/j.eprac.2021.11.085_bib28","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/HYPERTENSIONAHA.114.03850","article-title":"Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"64","author":"Muntner","year":"2014","journal-title":"Hypertension"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X21013975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X21013975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:13:28Z","timestamp":1761516808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X21013975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1530891X21013975"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2021.11.085","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening Rate for Primary Aldosteronism Among Patients With Apparent Treatment-Resistant Hypertension: Retrospective Analysis of Current Practice","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2021.11.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}